2013-09-30 13:08:43 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to AMAG Pharmaceuticals, Inc. (AMAG) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering AMAG Pharmaceuticals, Inc. (AMAG). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential AMAG Pharmaceuticals, Inc. investor.
Report Summary: AMAG Pharmaceuticals, Inc. is an above average quality company with a neutral outlook. AMAG Pharmaceuticals, Inc. has strong business growth and is run by mediocre management. The trend in AMAG Pharmaceuticals, Inc. fair value exchange rate against its closest rated-competitor, Response Genetics, Inc., has been appreciating over the past 2 weeks. When compared to its closest competitor, AMAG Pharmaceuticals, Inc. shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its
three components - business, management and price, performing an in-depth analysis of AMAG Pharmaceuticals, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.